Company Website

Contact Information:

Michael Jones
Cell: 857-275-0492
mjones2@blueprintmedicines.com

Tina Rodriguez
Cell: 832-343-1906
trodriguez@blueprintmedicines.com

 

Virtual Exhibit Hall Home

Blueprint Medicines is a global precision therapy company that aims to invent transformative medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

AYVAKIT® (avapritinib) is FDA approved for Advanced Systemic Mastocytosis, visit https://ayvakit.com/HCP/ for more information.
 

Learn more about GAVRETO® (pralsetinib) by visiting https://www.gavreto-hcp.com/#. Please see Important Safety Information on GAVRETO.

Gavreto RET+ mNSCLC All Treatment – Naïve Patients